Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics 

AACR-NCI-EORTC Conference, October 2021.

HER2-XPAT, A Novel Protease-Activated Prodrug T Cell Engager (TCE) With Potent T Cell Activation and Efficacy in Solid Tumor Models and Large Predicted Safety Margins in Non-Human Primates.

AACR Virtual Annual Meeting, April 2021.

HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates.

San Antonio Breast Cancer Symposium, December 2020.

HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates.

SITC Annual Meeting, November 2020.

HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), Engineered to Address On-Target, Off-Tumor Toxicity and Provide Large Predicted Safety Margins in Non-Human Primates.

ESMO Virtual Congress, September 2020.

HER2-XPAT and EGFR-XPAT: Pro-Drug T Cell Engagers (TCEs) Engineered to Address On-Target, Off-Tumor Toxicity With Potent Efficacy in vitro and in vivo and Large Safety Margins in NHP.

AACR Virtual Annual Meeting II, June 2020.

EGFR-XPAT, A Novel Prodrug T Cell Engager (TCE) Engineered to Address On-Target, Off-Tumor Toxicity and an Orthogonal Approach for Cancer Immunotherapy in EGFR, KRAS/BRAF Cancers.

ESMO Virtual Congress, September 2020.

HER2-XPAT and EGFR-XPAT: Pro-Drug T Cell Engagers (TCEs) Engineered to Address On-Target, Off-Tumor Toxicity With Potent Efficacy in vitro and in vivo and Large Safety Margins in NHP.

AACR Virtual Annual Meeting II, June 2020.

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.

NEJM, September 2020.

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Blood, February 2020.

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

American Society of Hematology, April 2020.

Podust V.N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.

Journal of Controlled Release 240: 52-66.

Moore W.V. et al. A randomized safety and efficacy study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency.

The Journal of Clinical Endocrinology and Metabolism 101(3):1091-1097.

Ding S. et al. Multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility.

Bioconjugate Chemistry 25(7):1351-1359.

Podust V.N. et al. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.

Protein Engineering, Design & Selection 26(11):743-753.

Yuen K.C.J. et al. A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone deficient adults.

The Journal of Clinical Endocrinology and Metabolism 98(6):2595-2603.

Alters S.E. et al. GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn’s disease model.

PLoS ONE 7(11):e50630.

Cleland J.L. et al. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.

Journal of Pharmaceutical Sciences 101(8):2744-2754.

Geething N.C. et al. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.

PLoS ONE 5(4):e10175.

Schellenberger V. et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.

Nature Biotechnology 27(12):1186-1190.